Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
Tubocurarine chloride is a neuromuscular blocking agent (NMB) administered via injection for use during anesthesia and surgery. It works by competitively binding to acetylcholine receptors at the neuromuscular junction, causing muscle paralysis. This legacy small-molecule drug has been largely replaced by newer agents with improved pharmacokinetic profiles.
Minimal team growth expected; this is a mature legacy product with limited commercial opportunity and declining relevance in modern anesthetic practice.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on tubocurarine chloride offers minimal career advancement opportunity; the product is a legacy asset in managed decline with virtually no job openings. This role is suitable only for professionals seeking stable, low-stress positions in product maintenance and compliance, not for those pursuing growth or innovation-driven careers.
Worked on TUBOCURARINE CHLORIDE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.